Compositions and Methods of Use For Treating Metabolic Disorders

Abstract

Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

1 - 52 . (canceled) 
     
     
         53 . A dimer comprising two polypeptides, each of the two polypeptides comprising the amino acid sequence of SEQ ID NO: 38. 
     
     
         54 . The dimer of  claim 53 , wherein at least one of the two polypeptides comprises an albumin fusion, wherein an albumin, an albumin variant, or an albumin fragment is conjugated to the at least one of the two polypeptides. 
     
     
         55 . The dimer of  claim 54 , wherein the albumin, albumin variant, or albumin fragment is human serum albumin, a human serum albumin variant, or a human serum albumin fragment, respectively, or bovine serum albumin, a bovine serum albumin variant, or a bovine serum albumin fragment, respectively, or cyno serum albumin, a cyno serum albumin variant, or a cyno serum albumin fragment, respectively. 
     
     
         56 . The dimer of  claim 54 , wherein the albumin, albumin variant, or albumin fragment is conjugated to at least one of the two polypeptides at the carboxyl terminus or the amino terminus. 
     
     
         57 . The dimer of  claim 56 , wherein the albumin, albumin variant, or albumin fragment is conjugated to at least one of the two polypeptides at the amino terminus. 
     
     
         58 . The dimer of  claim 56 , wherein the albumin, albumin variant, or albumin fragment is conjugated to the at least one of the two polypeptides via a linker. 
     
     
         59 . The dimer of  claim 58 , wherein the linker is a cleavable linker. 
     
     
         60 . The dimer of  claim 59 , wherein the cleavable linker can be cleaved by a protease. 
     
     
         61 . The dimer of  claim 58 , wherein the linker is a non-cleavable linker. 
     
     
         62 . The dimer of  claim 53 , wherein the dimer is N-glycosylated. 
     
     
         63 . A genetically modified mammalian host cell that expresses the dimer of  claim 53 . 
     
     
         64 . A pharmaceutical composition comprising the dimer of  claim 53  and a pharmaceutically acceptable diluent, carrier, or excipient. 
     
     
         65 . A pharmaceutical composition comprising the dimer of  claim 62  and a pharmaceutically acceptable diluent, carrier, or excipient. 
     
     
         66 . A sterile container comprising the pharmaceutical composition of  claim 65 . 
     
     
         67 . The sterile container of  claim 66 , wherein the sterile container is a syringe. 
     
     
         68 . A kit comprising the sterile container of  claim 66 . 
     
     
         69 . A method of treating obesity in a mammalian subject, the method comprising administering to the subject the dimer of  claim 53 , wherein the dimer is administered in an amount effective to treat obesity in the subject. 
     
     
         70 . The method of  claim 69 , wherein the administering is by parenteral injection. 
     
     
         71 . The method of  claim 70 , wherein the parenteral injection is subcutaneous. 
     
     
         72 . A method of treating hyperglycemia in a mammalian subject, the method comprising administering to the subject the dimer of  claim 53 , wherein the dimer is administered in an amount effective to treat the hyperglycemia in the subject. 
     
     
         73 . The method of  claim 72 , wherein the subject has diabetes mellitus. 
     
     
         74 . The method of  claim 72 , wherein the subject is human. 
     
     
         75 . The method of  claim 72 , wherein the subject is obese. 
     
     
         76 . The method of  claim 72 , wherein the administering is by parenteral injection. 
     
     
         77 . The method of  claim 76 , wherein the parenteral injection is subcutaneous. 
     
     
         78 . A method of treating obesity in a mammalian subject, the method comprising administering to the subject the dimer of  claim 62 , wherein the dimer is administered in an amount effective to treat obesity in the subject. 
     
     
         79 . The method of  claim 78 , wherein the administering is by parenteral injection. 
     
     
         80 . The method of  claim 79 , wherein the parenteral injection is subcutaneous. 
     
     
         81 . A method of treating hyperglycemia in a mammalian subject, the method comprising administering to the subject the dimer of  claim 62 , wherein the dimer is administered in an amount effective to treat the hyperglycemia in the subject. 
     
     
         82 . The method of  claim 81 , wherein the subject has diabetes mellitus. 
     
     
         83 . The method of  claim 81 , wherein the subject is human. 
     
     
         84 . The method of  claim 81 , wherein the subject is obese. 
     
     
         85 . The method of  claim 81 , wherein the administering is by parenteral injection. 
     
     
         86 . The method of  claim 85 , wherein the parenteral injection is subcutaneous.